---
title: "Trulicity (dulaglutide), all indications: Drug interactions questions"
description: "Drug interactions questions on Trulicity (dulaglutide) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What drug interactions does Trulicity have? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/trulicity/drug-interactions"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Trulicity (dulaglutide), all indications: Drug interactions questions

Manufacturer: Eli Lilly and Company  
Prescribing information: [Trulicity](https://uspl.lilly.com/trulicity/trulicity.html#pi)  
Indication pages: [Type 2 diabetes](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes)

## Drug interactions

<a id="trulicity-drug-interactions"></a>

### What drug interactions does Trulicity have?

> “TRULICITY delays gastric emptying and thus has the potential to reduce the rate of absorption of concomitantly administered oral medications. The delay in gastric emptying is dose-dependent but is attenuated with the recommended dose escalation to higher doses of TRULICITY [see Dosage and Administration (2.1)]. The delay is largest after the first dose and diminishes with subsequent doses. In clinical pharmacology studies, TRULICITY 1.5 mg did not affect the absorption of the tested orally administered medications to a clinically relevant degree [see Clinical Pharmacology (12.3)]. There is limited experience with the use of concomitant medications in clinical trials with TRULICITY doses of 3 mg and 4.5 mg.
>
> Monitor drug levels of oral medications with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with TRULICITY.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=TRULICITY%20delays%20gastric%20emptying%20and,when%20concomitantly%20administered%20with%20TRULICITY.)

> “When initiating TRULICITY, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions (5.3) and Adverse Reactions (6.1)].”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=When%20initiating%20TRULICITY%2C%20consider%20reducing,%285.3%29%20and%20Adverse%20Reactions%20%286.1%29%5D.)

> “In a clinical pharmacology study, the co-administration of a single dose of 1.5 mg dulaglutide with steady-state dose of 100 mg sitagliptin caused an increase in dulaglutide AUC and Cmax of approximately 38% and 27%, which is not considered clinically relevant.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=In%20a%20clinical%20pharmacology%20study%2C,is%20not%20considered%20clinically%20relevant.)

## Related pages
- [Medical information: Trulicity (dulaglutide): All indications](https://www.evicenter.com/medical-information/trulicity)
- [Indication](https://www.evicenter.com/medical-information/trulicity/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/trulicity/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/trulicity/safety)
- [Specific populations](https://www.evicenter.com/medical-information/trulicity/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/trulicity/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/trulicity/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/trulicity/access-and-coverage)
